PDCD1 and neoplasm: The binding of anti-PD1 or anti-PD-L1 antibodies to PD-1 or PD-L1, respectively, prevents the interaction between PD-1 and PD-L1 and results in the prolonged activation of T-cell responses, including potent tumour-specific immune responses [9].